D-0141-2024 Class II

Recalled by Wells Pharma Of Houston LLC — Houston, TX

FDA drug recall D-0141-2024 was initiated by Wells Pharma Of Houston LLC on Nov 22, 2023 and is designated Class II. Reason for recall: Lack of assurance of sterility. Affected quantity: 825 syringes.

Recall details

Product Type
Drugs
Report Date
Dec 13, 2023
Initiation Date
Nov 22, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
825 syringes

Product description

ceFAZolin sodium in Sterile Water for injection, Injectable Solution, 1g/10mL (0.1 g per mL), Syringe, Rx only, Wells Pharma, NDC 73702-131-10

Reason for recall

Lack of assurance of sterility.

Distribution pattern

Philadelphia, Pennsylvania.

Code information

Lot # 11092313110#01, Exp 01/12/24

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0141-2024
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0141-2024. Report a data issue: hello@regdatalab.com.